AVTX — Avalo Therapeutics Share News
0.000.00%
Last trade - 00:00- $399.54m
- $1.27m
- $0.06m
Avalo plunges after rival AbbVie's skin drug trial disappoints
NASDAQ RESUMED AT 09:36 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Avalo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Avalo Therapeutics Q2 net loss widens, driven by higher R&D expenses
Avalo Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Avalo Therapeutics - Selling Stockholders May Sell Up To 128,189 Shares Of Common Stock - SEC Filing
U.S. STOCKS ON THE MOVE-Strategy, Dell, Broadcom
U.S. STOCKS ON THE MOVE-Strategy, Solstice, Core Natural Resources
U.S. STOCKS ON THE MOVE-Core Natural Resources, GrabAGun, TeraWulf
Leerink starts Avalo at "outperform" on skin disease drug potential
Avalo Therapeutics Q1 net loss widens on increased R&D spend
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
U.S. STOCKS ON THE MOVE-DaVita, Knight-Swift, Madrigal Pharma
Avalo hits 2-yr high after skin disease drug meets main goal in study
U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber
U.S. STOCKS ON THE MOVE-AMD, Apollo, Deckers Outdoor
Avalo jumps after skin disease drug shows potential benefit in mid-stage trial